Key Points
- Director Eric Fain bought 20,000 shares of Orchestra BioMed at $4.13 each, a $82,600 transaction that increased his stake by 27.89% to 91,709 shares.
- OBIO shares rose 7.0% and recently opened at $3.98, with the stock trading well below its 1-year high of $5.42 and near its 50-day/200-day moving averages around $4.27–$4.28.
- The company recently reported a smaller-than-expected quarterly loss of $0.33 per share, though revenue came in below estimates; analysts currently rate the stock a Moderate Buy with an average target price of $14.50.
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) Director Eric Fain purchased 20,000 shares of the company's stock in a transaction that occurred on Thursday, May 14th. The shares were acquired at an average cost of $4.13 per share, for a total transaction of $82,600.00. Following the completion of the transaction, the director directly owned 91,709 shares of the company's stock, valued at $378,758.17. This trade represents a 27.89% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Orchestra BioMed Stock Up 7.0%
NASDAQ:OBIO opened at $3.98 on Tuesday. The firm has a market capitalization of $238.32 million, a price-to-earnings ratio of -4.10 and a beta of 0.52. Orchestra BioMed Holdings, Inc. has a 1-year low of $2.20 and a 1-year high of $5.42. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. The business's fifty day moving average price is $4.28 and its 200 day moving average price is $4.27.
Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.07. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%. On average, sell-side analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.62 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts recently weighed in on OBIO shares. Barclays upped their price target on Orchestra BioMed from $12.00 to $13.00 and gave the company an "overweight" rating in a research report on Wednesday, May 13th. Weiss Ratings lowered Orchestra BioMed from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, April 21st. Wall Street Zen lowered Orchestra BioMed from a "hold" rating to a "sell" rating in a research report on Saturday. Chardan Capital reissued a "buy" rating and set a $20.00 price target on shares of Orchestra BioMed in a research report on Thursday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Orchestra BioMed in a research report on Thursday, May 14th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Orchestra BioMed currently has an average rating of "Moderate Buy" and an average target price of $14.50.
Read Our Latest Analysis on OBIO
Institutional Trading of Orchestra BioMed
Large investors have recently made changes to their positions in the stock. AMH Equity Ltd bought a new stake in shares of Orchestra BioMed during the 3rd quarter worth about $412,000. Jane Street Group LLC bought a new stake in shares of Orchestra BioMed during the 2nd quarter worth about $50,000. XTX Topco Ltd bought a new stake in shares of Orchestra BioMed during the 2nd quarter worth about $45,000. Creative Planning bought a new stake in shares of Orchestra BioMed during the 2nd quarter worth about $40,000. Finally, Rice Hall James & Associates LLC bought a new stake in shares of Orchestra BioMed during the 1st quarter worth about $81,000. Institutional investors own 53.20% of the company's stock.
Orchestra BioMed Company Profile
(
Get Free Report)
Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.
Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
